Caitong International Asset Management Co. Ltd Has $33,000 Stake in Bruker Corporation $BRKR

Caitong International Asset Management Co. Ltd increased its position in shares of Bruker Corporation (NASDAQ:BRKR) by 1,354.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 800 shares of the medical research company’s stock after purchasing an additional 745 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Bruker were worth $33,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. CGN Advisors LLC increased its holdings in Bruker by 1.4% during the first quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company’s stock worth $919,000 after buying an additional 296 shares during the last quarter. New York State Teachers Retirement System increased its holdings in shares of Bruker by 0.8% in the first quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company’s stock valued at $1,549,000 after purchasing an additional 300 shares during the last quarter. State of Michigan Retirement System increased its holdings in shares of Bruker by 1.1% in the first quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company’s stock valued at $1,106,000 after purchasing an additional 300 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Bruker by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the medical research company’s stock valued at $1,294,000 after purchasing an additional 300 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of Bruker by 0.8% in the first quarter. KBC Group NV now owns 44,715 shares of the medical research company’s stock valued at $1,866,000 after purchasing an additional 349 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BRKR shares. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Bank of America reduced their target price on shares of Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Thursday, May 8th. Finally, Citigroup reduced their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research report on Monday, August 4th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $51.30.

Bruker Trading Down 0.4%

BRKR opened at $33.52 on Monday. Bruker Corporation has a twelve month low of $30.00 and a twelve month high of $72.94. The company has a 50-day simple moving average of $38.99 and a 200 day simple moving average of $41.61. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of 64.46, a P/E/G ratio of 2.77 and a beta of 1.16.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.52 EPS. Analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s dividend payout ratio is 38.46%.

Insider Activity at Bruker

In related news, CEO Frank H. Laukien bought 2,608 shares of the company’s stock in a transaction dated Friday, June 6th. The stock was purchased at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the acquisition, the chief executive officer owned 38,462,171 shares of the company’s stock, valued at $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.